GEMMABio Overview

  • Year Founded
  • 2024

Year Founded

  • Status
  • Private

  • Employees
  • 65

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $60M

  • Investors
  • 5

GEMMABio General Information

Description

Operator of a gene therapy platform designed to develop transformative treatments for rare diseases. The company offers next-generation AAV technology, platform-based gene therapy development, and expertise in genetic medicine and clinical development, enabling patients with rare diseases to access advanced genetic therapies.

Contact Information

Website
www.gemmabiotx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3025 John F. Kennedy Boulevard
  • Suite 220
  • Philadelphia, PA 19104
  • United States
+1 (445)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 3025 John F. Kennedy Boulevard
  • Suite 220
  • Philadelphia, PA 19104
  • United States
+1 (445)

GEMMABio Timeline

20252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GEMMABio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series A) 04-Aug-2026 $60M Completed Clinical Trials - General
3. Secondary Transaction - Private Completed Clinical Trials - General
2. Accelerator/Incubator $34M Completed Clinical Trials - General
1. Seed Round 23-Dec-2024 $34M $34M Completed Clinical Trials - General
To view GEMMABio’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

GEMMABio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GEMMABio Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Vox Capital Venture Capital Minority
Double Point Ventures Venture Capital Minority
Earlybird Venture Capital Venture Capital Minority
Savanne Life Sciences Corporate Venture Capital Minority
Penn Center for Innovation Accelerator/Incubator
To view GEMMABio’s complete investors history, request access »

Ready to get started?

Request a free trial

GEMMABio FAQs

  • When was GEMMABio founded?

    GEMMABio was founded in 2024.

  • Where is GEMMABio headquartered?

    GEMMABio is headquartered in Philadelphia, PA.

  • What is the size of GEMMABio?

    GEMMABio has 65 total employees.

  • What industry is GEMMABio in?

    GEMMABio’s primary industry is Drug Discovery.

  • Is GEMMABio a private or public company?

    GEMMABio is a Private company.

  • What is GEMMABio’s current revenue?

    The current revenue for GEMMABio is .

  • How much funding has GEMMABio raised over time?

    GEMMABio has raised $94M.

  • Who are GEMMABio’s investors?

    Vox Capital, Double Point Ventures, Earlybird Venture Capital, Savanne Life Sciences, and Penn Center for Innovation have invested in GEMMABio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process